CYP2C19 and transient ischemic attack: Finally, 8 articles published between 2014 and 2022 were included in the systematic review of the effect of CYP2C19 genotype on clinical outcomes of non-East Asian patients with stroke or TIA receiving clopidogrel therapy [17–19, 25–29].